Copy number alterations of <i>c‐MYC</i> and <i>PTEN</i> are prognostic factors for relapse after prostate cancer radiotherapy
Gaetano Zafarana(University Health Network), Robert G. Bristow(Princess Margaret Cancer Centre), Jennifer A. Locke(University Health Network), Adrian Ishkanian(University of Miami), Chad A. Malloff(University of British Columbia), Theodorus van der Kwast(Erasmus MC), Michael Milosevic(Princess Margaret Cancer Centre), Jenna Sykes(University Health Network), Varune Rohan Ramnarine(Beth Israel Deaconess Medical Center), Maisa Yoshimoto(University of Alberta), Alice Meng(University Health Network), Igor Jurisca(University Health Network), Melania Pintilie(University Health Network), Jeremy A. Squire(Universidade de São Paulo), John Thoms(University Health Network), Wan L. Lam(University of British Columbia)
Cited by 125
Related Papers
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study
|The Lancet Oncology|2010|944
Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma
|Journal of Clinical Oncology|2013|841
The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma
|The American Journal of Surgical Pathology|2020|705